Creating, facilitating, and promoting sustainable Health Technology Assessment (HTA) cooperation in Europe
PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB) – Final assessment now available
PTRCR15 – Remdesivir for the treatment of COVID-19. PICO and Evidence gaps – Final Rapid Collaborative Review now available
This is the first pharmaceutical Rapid Collaborative Review (PTRCR15) for – Remdesivir for
Patient group input requested for a new Joint Assessment on a medicinal product for acute myeloid leukaemia (AML).
EUnetHTA deems patient involvement very important in the production of Joint Assessment